Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 0.59 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12185602 | 0.91 | PRCP (0.70) | PRCPHTR2AHTR2CKCNH2ALDH1A1 | |
| SCHEMBL12185590 | 0.82 | PRCP (0.68) | PRCPHTR2AHTR1ADRD2DRD4 | |
| SCHEMBL12186022 | 0.82 | PRCP (0.68) | PRCPDRD2DRD4DRD3GRIN2B | |
| SCHEMBL12186038 | 0.82 | PRCP (0.63) | PRCPALDH1A1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL12185600 | 0.82 | PRCP (0.70) | PRCPKDM4ETSHRHTTHTR1A | |
| SCHEMBL14686433 | 0.81 | PRCP (0.52) | PRCPKCNH2ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14701380 | 0.80 | PRCP (0.53) | PRCPKCNH2ALDH1A1DRD2DRD4 | |
| SCHEMBL14686508 | 0.79 | PRCP (0.65) | PRCPKCNH2ALDH1A1DRD2DRD4 | |
| SCHEMBL12185546 | 0.77 | PLAT (0.50) | PRCPHTR1ASLC6A4SLC6A3 | |
| SCHEMBL14686543 | 0.75 | PRCP (0.64) | PRCPHTR2AHTR2CKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885HTR2A 4576/4885HTR2C 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.